Navigation Links
Tafinlar in Combination with Mekinist and Nivolumab Have Considerable Efficacy and Tolerability Advantages Over Currently Used Therapies for the Treatment of Unresectable Malignant Melanoma
Date:7/9/2013

BURLINGTON, Mass., July 9, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European oncologists indicate that overall survival is the factor that most influences their prescribing decisions for unresectable malignant melanoma, and that increased overall survival is associated with the highest level of unmet need. Interviewed thought-leaders are optimistic that Bristol-Myers Squibb/Ono Pharmaceuticals' nivolumab and GlaxoSmithKline's Tafinlar plus GlaxoSmithKline's Mekinist, in particular, will show advantages over sales-leading ipilimumab (Bristol-Myers Squibb's Yervoy) on this attribute.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The DecisionBase 2013 report entitled As Vemurafenib and Ipilimumab Gain Traction in the Market, What Key Attributes Will Differentiate Emerging Therapies According to Oncologists and Payers? finds that surveyed U.S managed care organization (MCO) pharmacy directors demand that emerging therapies provide significant improvements in overall survival over vemurafenib (Roche/Genentech/Daiichi Sankyo/Chugai's Zelboraf) to justify their cost and secure reimbursement. Vemurafenib is the premium-priced standard-of-care in unresectable malignant melanoma patients harboring the V600 BRAF mutation. Notably, a third of surveyed payers would not reimburse a new therapy priced the same as vemurafenib or higher that offers a six-month improvement in overall survival over vemurafenib, citing insufficient overall clinical benefit as one of the key reasons for not granting reimbursement.

The report also finds that surveyed U.S. and European oncologists identified hematological toxicity as the safety and tolerability attribute that is most important when making prescribing decisions in unresectable malignant melanoma, thus indicating the persisting high level of unmet need for therapies with a more favorable hematological profile.

"Despite the improvements effected by vemurafenib and ipilimumab on patient overall survival in unresectable malignant melanoma, our survey results suggest that both physicians and MCO pharmacy directors have high expectations of the requirements of emerging therapies to further extend survival," said Decision Resources Business Insights Analyst Samuel Mentzer, M.Sc. "Early-stage clinical data suggest that Tafinlar in combination with Mekinist and nivolumab have the potential to gain a competitive edge over ipilimumab and vemurafenib if they can replicate these promising results in their ongoing Phase III trials."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
2. Merrimack Pharmaceuticals Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors
3. In Relapsed/Refractory Multiple Myeloma, Thought Leaders Are Optimistic that the Combination of Carfilzomib, Lenalidomide and Dexamethasone Will Be the Most Efficacious Regimen
4. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
5. Actavis Confirms Early Stage Discussions Regarding Potential Combination with Warner Chilcott plc
6. Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets, Says Frost & Sullivan
7. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
8. Effectively Bringing Fixed Dose Combination Products to Market to Maintain Growth and Pipelines
9. Next-Generation Drug-Device Combinations Provide Innovative Delivery Methods for the Growing Biologics Market
10. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
11. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Pro X users can now reveal the media of their split screens with ...
(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
Breaking Medicine News(10 mins):